PDCD1 and pachyonychia congenita: The favourable systemic immune profile of PC patients leads us to the proposition that intraperitoneal application of therapeutic antibodies against PD-1, TIGIT, or VISTA could enhance their local efficacy whilst minimizing systemic toxicity.